.png){kind=icon}
.png){kind=icon}
Return
P21 Dalbavancin as long-term suppressive therapy for complex deep-seated infections: a retrospective service evaluation
.png){kind=icon}
OA
AI
J
F
D
I
V
H
DOI：10.1093/jacamr/dlag102.027.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Dalbavancin is a novel long-acting lipoglycopeptide antibiotic approved for acute bacterial skin and skin structure infections. Its unique pharmacokinetic profile has led to off-label use as suppressive therapy for deep-seated infections in some centres. This service evaluation reviews the use of suppressive Dalbavancin in a tertiary infection centre in Scotland.
Journal
J
IF:
3.3
Papers:
1.8K
Citations:
2.1K